Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging

Svetlana Halfon1, Natalie Abramov, Borislava Grinblat

  • 1Teva Pharmaceutical Industries, Rehovot, Israel .

Insights

Identifying reliable markers to distinguish mesenchymal stem cells (MSCs) from fibroblasts is crucial for cell therapy. New markers like CD106 and integrin alpha 11 show promise for MSC quality control.

Area of Science:

  • Cell Biology
  • Stem Cell Research
  • Biotechnology

Background:

  • Mesenchymal stem cells (MSCs) lose osteogenic potential with expansion, potentially due to fibroblast contamination.
  • Current MSC markers are also found on fibroblasts, hindering accurate identification.
  • Distinguishing MSCs from fibroblasts is vital for therapeutic applications and preventing tumor formation.

Purpose of the Study:

  • To identify novel markers that can reliably differentiate between bone marrow-derived MSCs and fibroblasts.
  • To evaluate the expression of these markers in MSCs at different passages and after specific treatments.
  • To establish methods for quality control of MSC cultures.

Main Methods:

  • Flow cytometry and small focused microarrays were used to analyze marker expression.
  • Real-time polymerase chain reaction (PCR) quantified gene expression differences.
  • Immunostaining and cell surface protein expression analysis were performed.
  • MSCs were treated with tumor necrosis factor-alpha (TNF-α) to assess CD106 regulation.

Main Results:

  • CD146 was exclusively expressed on MSCs.
  • CD106, integrin alpha 11, and insulin-like growth factor-2 showed significantly higher expression in MSCs compared to fibroblasts.
  • CD106, integrin alpha 11, and CD146 downregulated in later passage MSCs, while CD9 upregulated.
  • CD106 expression could be upregulated in MSCs by TNF-α treatment.

Conclusions:

  • Novel markers, including CD106, integrin alpha 11, and CD146, can effectively distinguish MSCs from fibroblasts.
  • These markers are valuable for assessing MSC quality during expansion, cryopreservation, and other manipulations.
  • The identified markers offer improved quality control for MSC-based therapies.